Clinical Trial Update: Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis [Phase 4]

View source ↗

Summary

This document reports the completion of a Phase 4 trial evaluating risperidone long-acting injectable in early psychosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperidone long-acting injectable (risperidone)

Snippet

Sponsor: Janssen Pharmaceutica N.V., Belgium | Conditions: Schizophrenia, Psychotic Disorders | Phase 4 | Status: COMPLETED